What is the first‑line treatment for uncomplicated tinea pedis (athlete’s foot)?

First-Line Treatment for Tinea Pedis

Topical terbinafine 1% cream applied twice daily for 1 week is the first-line treatment for uncomplicated tinea pedis, offering superior efficacy with the shortest treatment duration compared to all other topical antifungals. 1, 2

Topical Treatment Options

Preferred First-Line Agent

• Terbinafine 1% cream twice daily for 1 week achieves 66% effective cure rate and is more effective than longer courses of other antifungal agents. 1, 2
• The fungicidal action of terbinafine allows for this abbreviated 1-week course, compared to 4 weeks required for azole antifungals. 1, 3
• Terbinafine demonstrates 93.5% mycological cure at 4 weeks versus 73.1% for clotrimazole (p=0.0001), with effective treatment rates of 89.7% versus 58.7% respectively. 4
• A single-dose film-forming solution formulation is also available and may improve compliance. 1, 5, 6

Alternative Topical Agents

• Ciclopirox olamine 0.77% cream/gel twice daily for 4 weeks achieves approximately 60% clinical and mycological cure at end of treatment, increasing to 85% two weeks post-treatment. 1, 2
• Clotrimazole 1% cream twice daily for 4 weeks is less effective than both terbinafine and ciclopirox but remains widely available over-the-counter. 1, 2

When to Consider Oral Therapy

Reserve systemic antifungals for specific clinical scenarios: 1, 2

• Severe or extensive disease
• Failed topical therapy after appropriate duration
• Concomitant onychomycosis (nail infection serves as reinfection reservoir)
• Immunocompromised patients

Oral Treatment Options

• Oral terbinafine 250 mg once daily for 1-2 weeks provides similar mycological efficacy to 4 weeks of topical clotrimazole but with faster clinical resolution. 1, 2
• Oral itraconazole 100 mg daily for 2 weeks has comparable efficacy to oral terbinafine but may have slightly higher relapse rates. 1, 2
• Baseline liver function tests and complete blood count are recommended before initiating oral terbinafine in adults with hepatic or hematologic history, as rare but serious adverse events including neutropenia and hepatic failure have been reported. 1

Critical Prevention Measures to Prevent Recurrence

Patient Education

• Thoroughly dry interdigital spaces after bathing to reduce moisture that promotes fungal growth. 1, 2
• Apply antifungal foot powder after bathing reduces tinea pedis rates from 8.5% to 2.1%. 1, 2
• Change to cotton, absorbent socks daily to minimize moisture accumulation. 1, 2

Addressing Reinfection Sources

• Examine for concomitant onychomycosis, which requires extended oral terbinafine therapy (12-16 weeks) and acts as a persistent reservoir for foot reinfection. 1
• Decontaminate or discard contaminated footwear, as shoes harbor large numbers of viable dermatophyte spores. 1
• If shoes cannot be discarded, seal with naphthalene mothballs in a plastic bag for minimum 3 days, then air out thoroughly. 1
• Periodically spray terbinafine solution inside shoes for additional antifungal protection. 1
• Treat all infected household members simultaneously to prevent reinfection cycles within families. 1, 2

Common Pitfalls to Avoid

• Failing to obtain mycological confirmation before initiating therapy results in approximately 50% of cases being non-fungal, leading to unnecessary treatment. 1
• Neglecting to examine surrounding skin and nails when treating foot infection can miss concurrent onychomycosis that will cause treatment failure. 1
• Treating only the index patient without addressing subclinical infections in cohabitants leads to repeated episodes. 1
• Not addressing footwear contamination is a major source of recurrence even after successful initial treatment. 1

Special Populations

• Diabetic patients should receive terbinafine over itraconazole due to lower risk of drug interactions and hypoglycemia, particularly important as up to one-third of diabetics have onychomycosis that significantly predicts foot ulcer development. 1
• Athletes require minimum 72 hours of antifungal therapy before return to contact sports, with lesions covered by gas-permeable dressing. 1